HLS Therapeutics (TSE:HLS) Trading Down 1.2% – Here’s Why

HLS Therapeutics Inc. (TSE:HLS)’s share price traded down 1.2% during trading on Wednesday . The company traded as low as C$4.15 and last traded at C$4.15. 7,598 shares changed hands during trading, a decline of 63% from the average session volume of 20,668 shares. The stock had previously closed at C$4.20.

Analysts Set New Price Targets

Separately, Raymond James upped their price objective on shares of HLS Therapeutics from C$4.00 to C$5.00 in a research report on Friday, November 22nd.

HLS Therapeutics Stock Performance

The company has a current ratio of 1.56, a quick ratio of 1.01 and a debt-to-equity ratio of 86.50. The firm has a market capitalization of C$92.33 million, a price-to-earnings ratio of -4.16 and a beta of 1.07. The stock’s 50 day moving average price is C$3.97 and its two-hundred day moving average price is C$3.62.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.